|
1
|
Forouzanfar MH, Foreman KJ, Delossantos
AM, Lozano R, Lopez AD, Murray CJ and Naghavi M: Breast and
cervical cancer in 187 countries between 1980 and 2010: A
systematic analysis. Lancet. 378:1461–1484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Z, Wang H, Wang Z and Cai H: MiR-195
inhibits the proliferation of human cervical cancer cells by
directly targeting cyclin D1. Tumor Biol. 37:6457–6463. 2016.
View Article : Google Scholar
|
|
4
|
zur Hausen H: Papillomaviruses and cancer:
From basic studies to clinical application. Nat Rev Cancer.
2:342–350. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khan MJ, Castle PE, Lorincz AT, Wacholder
S, Sherman M, Scott DR, Rush BB, Glass AG and Schiffman M: The
elevated 10-year risk of cervical precancer and cancer in women
with human papillomavirus (HPV) type 16 or 18 and the possible
utility of type-specific HPV testing in clinical practice. J Natl
Cancer Inst. 97:1072–1079. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mariuzzi G, Santinelli A, Valli M, Sisti
S, Montironi R, Mariuzzi L, Alberti R and Pisani E: Cytometric
evidence that cervical intraepithelial neoplasia I and II are
dysplasias rather than true neoplasias. An image analysis study of
factors involved in the progression of cervical lesions. Anal Quant
Cytol Histol. 14:137–147. 1992.PubMed/NCBI
|
|
7
|
Zou DL, Zhou Q, Wang D, Guan L, Yuan L and
Li S: The downregulation of microRNA-10b and its role in cervical
cancer. Oncol Res. 24:99–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dueñas-Gonzalez A, Cetina L, Mariscal I
and de la Garza J: Modern management of locally advanced cervical
carcinoma. Cancer Treat Rev. 29:389–399. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebina Y, Mikami M, Nagase S, Tabata T,
Kaneuchi M, Tashiro H, Mandai M, Enomoto T, Kobayashi Y, Katabuchi
H, et al: Japan Society of Gynecologic Oncology guidelines 2017 for
the treatment of uterinecervical cancer. Int J Clin Oncol. Oct
5–2018.(Epub ahead of print). PubMed/NCBI
|
|
10
|
Glick SB, Clarke AR, Blanchard A and
Whitaker AK: Cervical cancer screening, diagnosis and treatment
interventions for racial and ethnic minorities: A systematic
review. J Gen Intern Med. 27:1016–1032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y,
Li Y, Wu Q and Deng Y: Intergrative microRNA and gene profiling
data analysis reveals novel biomarkers and mechanisms for lung
cancer. Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
|
|
14
|
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi
HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and
therapeutic targets of microRNAs in human gastric cancer. Int J Mol
Sci. 17(pii): E9452016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion,
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaukoniemi KM, Rauhala HE, Scaravilli M,
Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL and
Visakorpi T: Epigenetically altered miR-193b targets cyclin D1 in
prostate cancer. Cancer Med. 4:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilting SM, van Boerdonk RA, Henken FE,
Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ
and Steenbergen RD: Methylation-mediated silencing and tumor
suppressive function of hsa-miR-24 in cervical cancer. Mol Cancer.
9:1672010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Long MJ, Wu FX, Li P, Liu M, Li X and Tang
H: MicroRNA-10a targets CHL1 and promotes cell growth, migration
and invasion in human cervical cancer cells. Cancer Lett.
324:186–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invation, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: microRNA-142-3p inhibits cell proliferation and invasion
of cervical cancer cells by targeting FZD7. Tumor Biol.
36:8065–8073. 2015. View Article : Google Scholar
|
|
22
|
Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y
and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for
cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rogers K and Chen X: Biogenesis, turnover,
and mode of action of plant microRNAs. Plant Cell. 25:2383–2399.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Quan J, Li Y, Pan X, Lai Y, He T, Lin C,
Zhou L, Zhao L, Sun S, Ding Y, et al: Oncogenic miR-425-5p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 16:2175–2184. 2018.PubMed/NCBI
|
|
27
|
Fang F, Song T, Zhang T, Cui Y, Zhang G
and Xiong Q: MiR-425-5p promotes invasion and metastasis of
hepatocellular carcinoma cells through SCAI-mediated dysregulation
of multiple signaling pathways. Oncotarget. 8:31745–31757.
2017.PubMed/NCBI
|
|
28
|
Cristóbal I, Madoz-Gúrpide J, Rojo F and
García-Foncillas J: Potential therapeutic value of miR-425-5p in
metastatic colorectal cancer. J Cell Mol Med. 20:2213–2214. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Z, Wen M, Guo J, Shi J, Wang Z, Tan
B, Zhang G, Zheng X and Zhang A: Clinical value of miR-425-5p
detection and its association with cell proliferation and apoptosis
of gastric cancer. Pathol Res Pract. 213:929–937. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Susin SA, Lorenzo HK, Zamzami N, Marzo I,
Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler
M, et al: Molecular characterization of mitochondrial
apoptosis-inducing factor. Nature. 397:441–446. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Joza N, Susin SA, Daugas E, Stanford WL,
Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, et al:
Essential role of the mitochondrial apoptosis-inducing factor in
programmed cell death. Nature. 410:549–554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cregan SP, Dawson VL and Slack RS: Role of
AIF in caspase-dependent and caspase-independent cell death.
Oncogene. 23:2785–2796. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu D, Liu M, Wang W, Pang L, Wang Z, Yuan
C and Liu K: Overexpression of apoptosis-inducing factor
mitochondrion-associated 1 (AIFM1) induces apoptosis by promoting
the transcription of caspase-3 and DRAM in hepatoma cells. Biochem
Biophys Res Commun. 498:453–457. 2018. View Article : Google Scholar : PubMed/NCBI
|
